Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-2051 in Advanced Solid Tumors
NCT06265688Phase 1Recruiting
- Sponsor
- CytomX
- Start
- Apr 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CX-2051 in solid tumor (2 arms), sponsored by CytomX. Primary endpoints: Safety and tolerability of CX-2051 at 44 months and Recommended Phase 2 Dose at 44 months. Started Apr 2024; status: recruiting.
02
Drugs
CX-2051
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06265688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265688.